Luuk V. R.
- Country
- The Netherlands
- Department
- 1801: Neurology
Research Overview
- Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
- A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension
- Evaluation of Personalized B Cell-Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 19 of 92 partner sites.
Specializations
Neuroimmunology and Multiple Sclerosis
Luuk van Rooij is involved in multiple sclerosis research with a strong focus on treatment selection, relapse control, and individualized maintenance strategies. The clinical portfolio also includes related autoimmune disease activity and the use of B-cell–directed therapy in inflammatory neurological disease.
- Relapsing multiple sclerosis
- Ocrelizumab
- Rituximab
- Teriflunomide
Research activity also extends to personalized treatment intervals and comparative approaches in immune-mediated neurological care.
Stroke, Cerebrovascular Prevention, and Acute Neurology
His work includes ischemic stroke, transient ischemic attack, and secondary prevention after acute cerebrovascular events. The therapeutic scope covers antithrombotic strategies, vascular risk reduction, and outcomes in older patients with frailty and cerebrovascular disease.
- Secondary stroke prevention
- Antiplatelet and anticoagulant therapy
- High-risk transient ischemic attack
- Stroke recovery and functional outcome
Additional interests include cerebrovascular safety, bleeding risk, and optimization of long-term vascular protection.
Cardiovascular Disease and Vascular Medicine
Luuk van Rooij is active in clinical research on coronary artery disease, myocardial infarction, cardiogenic shock, and coronary vasospasm. His portfolio also spans lipid-lowering treatment, microvascular angina, calcific aortic valve stenosis, and prevention of major adverse cardiovascular events.
- Acute myocardial infarction
- Coronary microvascular dysfunction
- High cardiovascular risk
- Aortic valve disease
He is also involved in studies addressing vascular inflammation, endothelial dysfunction, and cardiovascular risk modification in chronic disease.
Hematologic Malignancies and Cellular Therapy
His research landscape includes chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. The therapeutic focus covers targeted agents, immunotherapy, and treatment sequencing in relapsed and newly diagnosed blood cancers.
- CLL
- Non-Hodgkin lymphoma
- Multiple myeloma
- Targeted hematologic therapy
Clinical interests also include residual disease assessment and consolidation strategies in hematologic oncology.
Oncology, Autoimmune Disease, and Multisystem Therapeutics
His trial activity extends across breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and non-small cell lung cancer, alongside immune-mediated disorders such as rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus, and Sjögren’s disease. The portfolio also includes chronic pancreatitis, burn injury, and sepsis.
- Solid tumor therapy
- Inflammatory rheumatic disease
- Gastrointestinal and pancreatic disease
- Critical care and infection
Research interests further cover endocrine and metabolic conditions, including thyroid disease, vasomotor symptoms, and reproductive health.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.